Silberstein Alzheimer’s Institute | NYU Langone Health
NYU Langone’s Silberstein Alzheimer’s Institute conducts research into the origins of memory disorders.
Simultaneous Multinuclear Magnetic Resonance Fingerprinting for Data Fusion of Quantitative Structural and Metabolic Imaging
This proposal seeks to perform an observational study, for evaluating a new non-invasive imaging technique that will provide multi-parametric metabolic 3D maps of the living brain at an unprecedented resolution, based on the fusion of simultaneously acquired proton and sodium MRI data. The new fused high-resolution structural and metabolic maps will provide new insights into neuro-architecture, neuro-biochemistry and their interconnection, which are crucial for our understanding of the human brain and its disorders. It will be tested for management of patients with chronic steno-occlusive disease and/or with recurrent transient ischemic attacks (TIA)/minor stroke).
Single-center observational longitudinal study to identify predictors of progression of joint damage after non-contact rupture of anterior cruciate ligament
Post-traumatic osteoarthritis (PTOA) is a common occurrence after anterior cruciate ligament (ACL) rupture independently of patient treatment, which indicates that early cellular and molecular changes directly after injury seem to be critical in disease development. The goal of this study is to develop a predictive model of progressionto PTOA using a combination of multinuclear magnetic resonance imaging markers, soluble synovial fluid biological markers, and biomechanical markers acquired on patients just after ACL injury, and at different time points after joint repair. This prognostic combination of biomarkers will help identify therapeutic targets and monitor theefficacy of intervention in the development of preventive treatments of PTOA.
SINGLE-CENTER OBSERVATIONAL STUDY OF SEIZURE TYPES IN RARE GENETIC EPILEPSIES
The purpose of this research study is to better describe specific movements that are seizures in rare genetic epilepsies (which may be different than other more common epilepsy syndromes). This can help parents and doctors perform seizure counts more accurately. This will help individual patients and doctors with medication management and evaluate how well patients are doing over time. On a larger scale, this study can also help specific rare genetic epilepsy syndromes when there is a genetic or drug trial to ensure accurate seizure counting is being performed, and to better determine if an intervention is truly helping with seizures.
Single-Center Pilot Study of Living Donor Kidney Transplant from HIV-positive Donor to HIV-positive Recipient
This study will evaluate the feasibility and safety of living donor kidney transplant from an HIV-infected donor to an HIV-infected recipient.
Single-center study of pupillary dilation during post-auricular vagal nerve stimulation
We will evaluate pupillary dilation from vagal nerve stimulation of Arnold’s Nerve, a branch of the vagus nerve, during routine cochlear implantation surgery. Vagal nerve stimulation has the potential to improve performance on cognitive tasks.
Sinonasal Cancer | NYU Langone Health
Doctors at Perlmutter Cancer Center manage sinonasal cancer with surgery, radiation therapy, and chemotherapy.
Sinonasal Disorder Services for Children | NYU Langone Health
Specialists at Hassenfeld Children’s Hospital at NYU Langone create child-centered care plans to manage disorders affecting the nose and sinus.
Site for A 78-week trial comparing the effect and safety of once weekly insulin icodec and once daily insulin glargine 100 units/mL both in combination with non-insulin anti-diabetic treatment in insulin na ve subjects with type 2 diabetes
Site for To demonstrate the effect on glycaemic control of once weekly insulin 287, with or without non-insulin anti-diabetic drugs, in insulin naïve subjects with T2D. This includes comparing the difference in change from baseline in HbA1c between insulin 287 and insulin glargine 100 units/mL after 52 weeks of treatment to a non-inferiority limit of 0.3%.To compare parameters of glycaemic control and safety of once weekly insulin 287 with once daily insulin glargine 100 units/mL, both with or without non-insulin antidiabetic drugs, in insulin naïve subjects with T2D.
Site for A Multi-Center Prospective Randomized Controlled Trial Comparing the Safety and Effectiveness of prodisc C SK and prodisc C Vivo to Mobi-C Cervical Disc in the Treatment of Two-Level Symptomatic Cervical Disc Disease (SCDD)
Research study to evaluate the safety and effectiveness of prodisc C SK and prodisc C Vivo versus Mobi-C (currently available on market).